We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Keywords: COVID-19; dupilumab; infectious disease; type 2 immunity.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.